(Q35035407)

5 August 2017

0 references

1 reference

title

Statistical challenges in the evaluation of surrogate endpoints in randomized trials (English)

1 reference

5 August 2017

0 references

2

Marc Buyse

0 references

Tomasz Burzykowski

object named as

Tomasz Burzykowski

5

0 references

Geert Molenberghs

1

object named as

Geert Molenberghs

1 reference

5 August 2017

Helena Geys

3

1 reference

5 August 2017

Didier Renard

4

1 reference

5 August 2017

Ariel Alonso

6

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Contemporary Clinical Trials

5 August 2017

1 reference

5 August 2017

23

1 reference

5 August 2017

607-625

1 reference

5 August 2017

6

1 reference

Surrogate endpoints in clinical trials: cancer

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Criteria for the validation of surrogate endpoints in randomized experiments.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Statistical validation of intermediate endpoints for chronic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Meta-analysis for the evaluation of potential surrogate markers.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

The validation of surrogate endpoints in meta-analyses of randomized experiments.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

On meta-analytic assessment of surrogate outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Estimating the proportion of treatment effect explained by a surrogate marker.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Estimating the proportion of treatment effect explained by a surrogate marker

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Reliability and validity of the positive and negative syndrome scale for schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Global cross-ratio models for bivariate, discrete, ordered responses

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900236-2

7 January 2021

10.1016/S0197-2456(02)00236-2

Identifiers

DOI

1 reference

5 August 2017

1 reference